Biozone Pharmaceuticals, Inc. (OTCBB:BZNE) Held Down by Selling

Bordering the weekend, selling held down Biozone Pharmaceuticals, Inc. (OTCMKTS:BZNE), the newly active pharmaceutical stock that is yet expected to make a sensation. BZNE slid down more than 11% on Monday, down to $0.755 on selling volumes above $1.8 million.

The latest mention for BZNE comes from review site The Street, where BZNE is lauded for its 80% rise last week. The rise was attributed to the attrition in the activity of a large seller that initially pressured the price down toward the 40-cent range. Once the selling pressure cleared, BZNE took off, with a lesser correction in the past two trading days. And BZNE is moving into uncharted levels, with the sky the limit as the company’s business promise will just begin to shine through its share levels.

Still, BZNE has not posted any news of its own, to show what direction it would be taking. The new week would again test the strength of this ticker, which is not promoted in emails.

BZNE has its own story, but it also participates in a general revival of pharmaceutical tickers, which are again among the most actively traded on the OTC markets.

Titan Pharmaceuticals, Inc. (OTCBB:TTNP) was also active last week, wrestling to keep closer to the $1 levels. For this relatively large pharmaceutical bid, the predictions for a long run to a few dollars’ worth are not fulfilled for now.

Another pharma stock that is on an upward leg is AP Pharma, Inc. (OTCBB:APPA), trying to reach the 48-cent ranges that it touched for a while in months back, only to slide to lows of around 30 cents. APPA had a week of buying, taking it from 38 cents to 43.

Investors’ message boards are optimistic about an upward drive in the BZNE stock. The rise in BZNE also coincides with a good period for the company of Dr. Philip Frost, Opko Health (NYSE:OPK). Dr. Frost is the founding investor for BZNE, adding its patents and activities to the portfolio of Opco by setting up a large position in the company.

If you still await an even better run for BZNE, keep in mind that the ticker has erased value in the past and has come under pressure. Avoid investing unaffordable sums and choose your time horizon well, after researching for yourself the true potential of this company.